AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16404866
Drug: ARTRA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTRA (500 mg glucosamine hydrochloride + 500 mg chondroitine sulphate) taken 1 tablet 2 times a day for the first month, then 1 tablet a day for the following 5 months, along with diclofenac sodium 50 mg 2 times a day with gradual decrease as pain decreased.
Trial: 16404866
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg twice a day for 6 months (control group).
Trial: 10470627
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg i.v. followed by continuous infusion of 170 micrograms kg‐1 min‐1 (with additional 0.5 mg/kg if needed)
Trial: 10470627
Drug: Sevoflurane 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 5% inhalation
Trial: 1989740
Drug: Promethazine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (0.5 mg.kg‐1 IV + 0.5 mg.kg‐1 IM)
Trial: 1989740
Drug: Droperidol (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.075 mg.kg‐1 IV + physiological saline, 0.02 ml.kg‐1 IM)
Trial: 27923685
Drug: LVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVR with vehicle solution (Group 2)
Trial: 27923685
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution without LVR (Group 3)
Trial: 9667681
Drug: r‐HuEPO (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO (200 units kg(‐1) day(‐1) plus oral iron supplements 325 mg p.o. t.i.d.)
Trial: 9667681
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no r‐HuEPO treatment)
Trial: 28283830
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of fluoroquinolone treatment
Trial: 28283830
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of fluoroquinolone treatment
Trial: 21982411
Drug: Dalcetrapib 900
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 900 mg plus Ezetimibe 10 mg
Trial: 11029965
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Cu‐glycine chelate
Trial: 11029965
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg Cu‐glycine chelate
Trial: 8851594
Drug: Ceftazidime as
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime as intermittent bolus (IB) 2 g i.v. every 8 h (q8h) for 2 days
Trial: 8851594
Drug: Ceftazidime as
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime as continuous infusion (CI) 3 g continuous infusion over 24 h for 2 days
Trial: 8851594
Drug: Ceftazidime (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (both regimens) in presence of tobramycin (4 to 7 mg/kg i.v. q24h)
Trial: 6703681
Drug: Ceforanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceforanide (1 g every 12 h)
Trial: 6703681
Drug: Cephapirin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephapirin (2 g every 4 h)
Trial: 30014664
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride tablets
Trial: 26968285
Drug: Immediate intramasseteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate intramasseteric injection of 2ml of 8mg/2ml dexamethasone
Trial: 26968285
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 2ml of sterile saline solution
Trial: 25666690
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy plus TrP‐DN (n = 10)
Trial: 25666690
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (n = 10)
Trial: 23073338
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment with inactivity on fundus fluorescein angiography at month 3
Trial: 23073338
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment with qualitative OCT inactivity at month 5
Trial: 23073338
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment with qualitative OCT inactivity at month 8
Trial: 23073338
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment with leakage on OCT
Trial: 23073338
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment with inactivity on fundus fluorescein angiography at months 3 and 5
Trial: 20695184
Drug: Preoperative bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative bowel preparation procedure (Group B)
Trial: 20695184
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative bowel preparation (Group A)
Trial: 11221150
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) and Fluvoxamine (FVX)
Trial: 9095122
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) intravenous up to 30 ng/kg/min for 72 hours after surgery
Trial: 8229122
Drug: 160 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/d of megestrol acetate
Trial: 8229122
Drug: 800 mg/d
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/d of megestrol acetate
Trial: 8229122
Drug: 1,600 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,600 mg/d of megestrol acetate
Trial: 3782653
Drug: Polyethylene glycol-modified
RxNorm normalized name: Polyethylene glycol-modified uricase
DrugBank: PEG-uricase (DB05321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-modified ragweed extract administered via weekly injections
Trial: 3782653
Drug: Polyethylene glycol-modified
RxNorm normalized name: Polyethylene glycol-modified uricase
DrugBank: PEG-uricase (DB05321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-modified ragweed extract administered via daily injections until adverse reaction, then switched to weekly schedule
Trial: 24022270
Drug: Daclizumab high-yield
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab high-yield process (DAC HYP) 150 mg or 300 mg, administered subcutaneously every four weeks for 52 weeks
Trial: 24022270
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered subcutaneously every four weeks for 52 weeks
Trial: 21383045
Drug: MK-3207 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3207 200 mg
Trial: 21383045
Drug: MK-3207 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3207 100 mg
Trial: 21383045
Drug: MK-3207 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3207 10 mg
Trial: 11082723
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with concomitant chemotherapy (arm B)
Trial: 30220407
Drug: PAXG (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAXG (cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 every 4 weeks)
Trial: 30220407
Drug: nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Trial: 27681755
Drug: Both dose
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dose levels of SIB-VMAT
Trial: 11494543
Drug: Prolonged IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged IFN therapy
Trial: 11494543
Drug: IFN-beta therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta therapy twice a day
Trial: 11494543
Drug: IFN-beta therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta therapy daily for 24 weeks
Trial: 11494543
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of IFN-alpha and IFN-beta
Trial: 11494543
Drug: Standard IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IFN therapy
Trial: 9593129
Drug: Cefdinir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (300 mg twice a day for 5 days)
Trial: 1838978
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (250 mg four times a day for 10 days)
Trial: 31589545
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with Cochlear Implants (CCIs)
Trial: 31589545
Drug: Postlingually deaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postlingually deaf adults with Cochlear Implants (CIs)
Trial: 29850937
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg (pre-hemodialysis)
Trial: 29850937
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg (post-hemodialysis)
Trial: 29850937
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg (healthy subjects)
Trial: 29850937
Drug: Ticagrelor (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (all treatments)
Trial: 25230867
Drug: HVHF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVHF treatment (18 hours per day on days 1, 3, 5, 7)
Trial: 25230867
Drug: PiCCO +
RxNorm normalized name: STATLOCK PICC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PiCCO + HVHF treatment
Trial: 22412215
Drug: Survey administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey administered to both groups
Trial: 17690799
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral therapy (ICBT)
Trial: 16218176
Drug: Once-daily saquinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 12117728
Drug: Dihydrotestosterone (DHT)
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (DHT) 70 mg transdermally daily
Trial: 12117728
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human chorionic gonadotropin (rhCG) 250 microg twice weekly
Trial: 388053
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor (TF) treatment, 2 units of TF administered subcutaneously on days 1 and 15
Trial: 8993769
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor (TF) treatment
Trial: 31479138
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR target 1.8)
Trial: 31479138
Drug: Standard-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-intensity warfarin (INR target 2.5)
Trial: 27484766
Drug: Aidi intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aidi intravenous injection plus NP regimen (2 cycles)
Trial: 27484766
Drug: Aidi intratumor
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRATUMOR LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aidi intratumor injection plus NP regimen (2 cycles)
Trial: 25933151
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine HCl + 1/200,000 epinephrine (10 mL)
Trial: 25933151
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine HCl + 1/200,000 epinephrine (10 mL)
Trial: 25933151
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (10 mL)
Trial: 19732673
Drug: Precomprehensive orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precomprehensive orthodontic treatment
Trial: 19732673
Drug: Postinterceptive orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postinterceptive orthodontic treatment
Trial: 19732673
Drug: Overall and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall and oral health QoL
Trial: 9732919
Drug: Eradicating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradicating treatment (Group 1)
Trial: 9732919
Drug: Eradicating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradicating treatment (Group 2 after initial follow-up)
Trial: 8277068
Drug: Heparin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (15 IU/kg body weight per h) with aspirin
Trial: 23895505
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1 g twice daily
Trial: 23895505
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and Aspirin combination
Trial: 23895505
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Aspirin
Trial: 20880282
Drug: Feeding daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding daily to satiation (FD)
Trial: 15479360
Drug: Intravenous lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lansoprazole 30 mg
Trial: 15479360
Drug: Oral lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lansoprazole 30 mg
Trial: 11340101
Drug: Oats diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oats diet (45 g/(4.2 MJ dietary energy. d), n = 22)
Trial: 26080338
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (intravenous ertapenem 1 g/d for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Trial: 26080338
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (standard open appendectomy)
Trial: 22008822
Drug: PCV13 toddler
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 toddler dose
Trial: 20107684
Drug: Beverage mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage mixed with 25 g of rapadura and 40 mg of ascorbic acid (per 200-mL serving)
Trial: 20107684
Drug: Beverage sweetened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage sweetened with 25 g of standard refined sugar and 40 mg of ascorbic acid (per 200-mL serving)
Trial: 15639694
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/d
Trial: 11005269
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy for 6 months
Trial: 11005269
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy for 12 months
Trial: 3086024
Drug: L‐rhamnose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐rhamnose
Trial: 3419838
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (US) at 0.1 W/cm2
Trial: 27554689
Drug: Thigh-high 30-40
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh-high 30-40 mm Hg compression therapy for 7 days
Trial: 24524874
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no physical therapy)
Trial: 16213869
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (dosage not specified)
Trial: 3389864
Drug: Oxandrolone, 2.5
RxNorm normalized name: Oxandrolone, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone, 2.5 mg per day (mean dose 0.072 mg/kg/day)
Trial: 3389864
Drug: Oxandrolone, 2.5
RxNorm normalized name: Oxandrolone, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone, 2.5 mg per day (mean dose 0.073 mg/kg/day) after placebo
Trial: 31199462
Drug: methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate (0.3 mg/kg, twice a day for 2 weeks)
Trial: 23927594
Drug: Cynatine® FLX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cynatine® FLX (500 mg per day for 60 days)
Trial: 23927594
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, identical dosage for 60 days)
Trial: 17583186
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (1000 mg)
Trial: 16702006
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at an initial dose of 0.003 mg/kg/day for 4 weeks, increased to 0.006 mg/kg/day for 4 weeks, and then to 0.012 mg/kg/day for the last 16 weeks
Trial: 7947061
Drug: Conventional dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dressing and compression therapy
Trial: 27787443
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab plus DHA (1,050 mg/day)
Trial: 19653341
Drug: Imipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25 mg, allowed to double at week 2 if needed)
Trial: 15113952
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (120 mg iron as ferrous sulfate and 0.5 mg folic acid)
Trial: 15113952
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron supplementation (60 mg iron and 0.25 mg folic acid)
Trial: 22888611
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron supplementation
Trial: 11306774
Drug: Amantadine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (500 ml i.v. daily for 5 days)
Trial: 9522320
Drug: cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyproterone acetate (5 mg p.o.)
Trial: 9522320
Drug: nomegestrol acetate
RxNorm normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: nomegestrol acetate (5 mg p.o.)
Trial: 9522320
Drug: progesterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: progesterone (100 mg, vaginal cream)
Trial: 7699945
Drug: HLBI-VCAP combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLBI-VCAP combination therapy (Interferon-alpha + VCAP chemotherapy)
Trial: 7699945
Drug: VCAP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCAP chemotherapy alone
Trial: 27806875
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D3 supplementation
Trial: 24687891
Drug: Continuous device-aided
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous device-aided drug delivery